Given that we (and the markets,I hope)are expecting a small loss this quarter, what might we see in tomorrow's report which will "counter" the possible negative effect of that loss? I have some AVN investors here who are concerned about this loss, and I want to be able to tell them, "Yes, but, the report should also say........" Thanks.
The losses on the books are the result revenue from the introduction of Abreva, AVN no longer has a burn rate but a revenue stream this should improve as Abreva gains market penetration. Xenerex's burn rate is expected to be continully reduced throughout this year as they sign more deals with other companies. Or at least that is how I explained it to my friends. JMHO
Who in their right mind would worry about the loss, when it has been expected, since we can only post the royalties from the first three months of the launch, which is more like two months (Nov. and Dec.)? We should be seeing profits from here on out. IMHO......It is almost time for the Canadian TTP to give us approval, which should increase sales from the 10.15 million done Jan. through Mar. And how about those line extensions with GSK. I hope to see something soon.
Yes, But the report should also say, "Even though roll-out figures for Abreva were thus, we have also received our check from GSK, for JFM 2001 and it was substantially higher! Our subsidiary, Exenerex, has signed its first mouse partner with 5-6 more to be signed shortly. Our trials with AVP-923 are progressing nicely, and we expect approval from FDA. Etc.